Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product liability

This article was originally published in The Tan Sheet

Executive Summary

Senate does not agree to close debate on S 687 on June 29, effectively killing the bill for this congressional session. After losing two cloture votes on the bill, which would establish a uniform product liability code, bill supporters succumbed to a filibuster in the face of the Senate's tight legislative schedule. Following a first cloture vote June 28, which failed 54-44, chief sponsor Sen. Jay Rockefeller (D-W.Va.) agreed to support an amendment offered by Sens. Byron Dorgan (D-N.D.) and Carol Moseley-Braun (D-Ill.) to eliminate a provision of S 687 that would limit liability for punitive damages for makers of drugs or devices that have received premarket approval from FDA. However, a second cloture vote failed 57-41 before the amendment could be brought up for a vote

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS082981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel